CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and more
negativeNegative
AI Analysis
Summary
Novartis halted immunology and neuroscience studies for an experimental CAR-T therapy following deaths of three patients. The article also mentions Eli Lilly's 13th acquisition of 2026.
Clinical Trial Data
Patients
3
Outcome Details
Three patient deaths reported; Novartis paused immunology and neuroscience studies for experimental CAR-T therapy
Importance:9/10
Sentiment:
-0.95
CAR-Tsafetyclinical holdpatient deathsimmunologyneuroscience
Read the original article
Published by Endpoints News on September 5, 2026 10:00 AM